Ken Griffin Kempharm, Inc Transaction History
Citadel Advisors LLC
- $550 Billion
- Q2 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Kempharm, Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 114,267 shares of KMPH stock, worth $564,478. This represents 0.0% of its overall portfolio holdings.
Number of Shares
114,267
Previous 92,800
23.13%
Holding current value
$564,478
Previous $458,000
23.14%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding KMPH
# of Institutions
131Shares Held
32.7MCall Options Held
379KPut Options Held
611K-
Woodline Partners LP San Francisco, CA4.62MShares$22.8 Million0.13% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA4.17MShares$20.6 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.95MShares$14.6 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.7MShares$13.3 Million0.0% of portfolio
-
Rubric Capital Management LP New York, NY1.96MShares$9.67 Million0.22% of portfolio
About KEMPHARM, INC
- Ticker KMPH
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,493,600
- Market Cap $170M
- Description
- KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds t...